ANGO

Company Overview — What Does ANGIODYNAMICS INC Do?

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York. ANGIODYNAMICS INC (ANGO) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO James C. Clemmer and employs approximately 760 people, headquartered in Wilmington, New York. With a market capitalization of $492M, ANGO is one of the notable companies in the Healthcare sector.

ANGIODYNAMICS INC (ANGO) Stock Rating — Reduce (April 2026)

As of April 2026, ANGIODYNAMICS INC receives a Reduce rating with a composite score of 31.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ANGO ranks #3,697 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ANGIODYNAMICS INC ranks #611 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ANGO Stock Price and 52-Week Range

ANGIODYNAMICS INC (ANGO) currently trades at $9.62. The stock lost $0.47 (4.7%) in the most recent trading session. The 52-week high for ANGO is $13.99, which means the stock is currently trading -31.3% from its annual peak. The 52-week low is $8.36, putting the stock 15.0% above its annual trough. Recent trading volume was 300K shares, suggesting relatively thin trading activity.

Is ANGO Overvalued or Undervalued? — Valuation Analysis

ANGIODYNAMICS INC (ANGO) carries a value factor score of 32/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.31x, versus the sector average of 2.75x. The price-to-sales ratio is 1.31x, compared to 1.66x for the average Healthcare stock.

At current multiples, ANGIODYNAMICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ANGIODYNAMICS INC Profitability — ROE, Margins, and Quality Score

ANGIODYNAMICS INC (ANGO) earns a quality factor score of 31/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -17.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.4% versus the sector average of -33.1%.

On a margin basis, ANGIODYNAMICS INC reports gross margins of 54.6%, compared to 71.5% for the sector. The operating margin is -13.0% (sector: -66.1%). Net profit margin stands at -9.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 7.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ANGO Debt, Balance Sheet, and Financial Health

ANGIODYNAMICS INC has a debt-to-equity ratio of 50.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.35x, indicating strong short-term liquidity.

ANGO has a beta of 1.07, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ANGIODYNAMICS INC is 49/100, reflecting average volatility within the normal range for its sector.

ANGIODYNAMICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ANGIODYNAMICS INC reported revenue of $306M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-30M. Gross margin was 54.6%. Operating income came in at $-40M.

In Q3 2026, ANGIODYNAMICS INC reported revenue of $78M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-8M. Gross margin was 52.9%. Revenue grew 8.9% year-over-year compared to Q3 2025. Operating income came in at $-13M.

In Q2 2026, ANGIODYNAMICS INC reported revenue of $79M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-6M. Gross margin was 56.4%. Revenue grew 9.0% year-over-year compared to Q2 2025. Operating income came in at $-6M.

In Q1 2026, ANGIODYNAMICS INC reported revenue of $76M and earnings per share (EPS) of $-0.26. Net income for the quarter was $-11M. Gross margin was 55.3%. Revenue grew 12.2% year-over-year compared to Q1 2025. Operating income came in at $-11M.

Over the past 8 quarters, ANGIODYNAMICS INC has demonstrated a growth trajectory, with revenue expanding from $67M to $306M. Investors analyzing ANGO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ANGO Dividend Yield and Income Analysis

ANGIODYNAMICS INC (ANGO) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ANGO Momentum and Technical Analysis Profile

ANGIODYNAMICS INC (ANGO) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ANGO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ANGIODYNAMICS INC (ANGO) ranks #611 out of 838 stocks based on the Blank Capital composite score. This places ANGO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ANGO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ANGO vs S&P 500 (SPY) comparison to assess how ANGIODYNAMICS INC stacks up against the broader market across all factor dimensions.

ANGO Next Earnings Date

No upcoming earnings date has been announced for ANGIODYNAMICS INC (ANGO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ANGO? — Investment Thesis Summary

The quantitative profile for ANGIODYNAMICS INC suggests caution. The quality score of 31/100 flags below-average profitability. The value score of 32/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance.

In summary, ANGIODYNAMICS INC (ANGO) earns a Reduce rating with a composite score of 31.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ANGO stock.

Related Resources for ANGO Investors

Explore more research and tools: ANGO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ANGO head-to-head with peers: ANGO vs AZN, ANGO vs SLGL, ANGO vs VMD.